Journal: bioRxiv

Article Title: Inhibition of peripheral VEGF signaling rapidly reduces leucocyte obstructions in brain capillaries and increases cortical blood flow in an Alzheimer’s disease mouse model

doi: 10.1101/2021.03.05.433976

Figure Lengend Snippet: ELISA measurements of VEGF1R receptor ( A ), VEGF2R receptor ( B ) from brain lysates, and soluble VEGF1R receptor ( C ), and soluble VEGF2R receptor ( D ) from plasma samples after 1 week of anti-VEGF-A treatment or saline injections in APP/PS1 and WT mice (n=3 mice per group). Kruskal-Wallis test with multiple comparison correction to compare across groups. In all graphs each point represents the ELISA measurement from one mouse, red horizontal line represents the median; * indicates p = 0.05.

Article Snippet: After the measuring the concentrations ELISAs were performed following the manufacture’s protocol (VEGF1R (MVR100) and VEGF2R (MVR200B), R&D Systems).

Techniques: Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Saline, Comparison

Journal: bioRxiv

Article Title: Cross-family Signaling: PDGF Mediates VEGFR Activation and Endothelial Function

doi: 10.1101/2025.02.27.640684

Figure Lengend Snippet: HBMECs were starved with low-serum medium for 6 hours and stimulated with growth factors at the indicated concentrations for 30 min (VEGFR1) or 10 min (VEGFR2). The receptor activation was picked up either by ELISA detecting the pan-tyrosine phosphorylation of VEGFR1 (A–C) or VEGFR2 (D) , or by immunoblotting and probed with primary antibody targeting VEGFR2 phosphorylation at tyrosine site 1175 (E) .

Article Snippet: After being briefly vortexed and centrifuged at 12,000× g for 10 min at 4 °, the cell lysates went through the protocol of Human Phospho-VEGFR1/Flt-1 DuoSet IC ELISA kit (R&D Systems, DYC4170), Human Phospho-VEGFR2/KDR DuoSet IC ELISA kit (R&D Systems, DYC1766), or Human Phospho-PDGFRβ DuoSet IC ELISA kit (R&D Systems, DYC1767) to assess the phosphorylation levels of VEGFR1, VEGFR2, or PDGFRβ, respectively.

Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay, Western Blot

Journal: bioRxiv

Article Title: Cross-family Signaling: PDGF Mediates VEGFR Activation and Endothelial Function

doi: 10.1101/2025.02.27.640684

Figure Lengend Snippet: (A– G) HDMEC ( PDGFRA −/− and PDGFRB −/− ) were starved with low-serum medium for 6 hours and stimulated with growth factors at the indicated concentrations for 30 min (VEGFR1) or 10 min (VEGFR2). (A–C) The fold changes of VEGFR1 phosphorylation induced were assessed via ELISA. (D–G) The fold changes of VEGFR1 phosphorylation induced were assessed via immunoblotting. (H) The fold changes of PDGFRβ phosphorylation in HDFs induced by 30-min VEGF-A or PDGF-BB treatment were measured via ELISA.

Article Snippet: After being briefly vortexed and centrifuged at 12,000× g for 10 min at 4 °, the cell lysates went through the protocol of Human Phospho-VEGFR1/Flt-1 DuoSet IC ELISA kit (R&D Systems, DYC4170), Human Phospho-VEGFR2/KDR DuoSet IC ELISA kit (R&D Systems, DYC1766), or Human Phospho-PDGFRβ DuoSet IC ELISA kit (R&D Systems, DYC1767) to assess the phosphorylation levels of VEGFR1, VEGFR2, or PDGFRβ, respectively.

Techniques: Enzyme-linked Immunosorbent Assay, Western Blot

Journal: Science Advances

Article Title: Murine vascular organoids are responsive and adaptable 3D systems with cellular heterogeneity and dynamic plasticity

doi: 10.1126/sciadv.ady4738

Figure Lengend Snippet: ( A ) Schematic of outside-in treatments to induce inflammation of mBVOs. ( B ) Cryosections of treated mBVOs stained for CD31, ICAM-1, and RelB; arrowheads indicate CD31 + /ICAM-1 + or CD31 + /RelB + cells, and stars indicate CD31 − /ICAM-1 + or CD31 − /RelB + cells. Scale bars, 50 μm. ( C ) Image quantifications of ICAM-1 + areas upon treatments. ( D ) Image quantifications of nuclear RelB + cells upon treatments, n = 3 mBVO differentiations (mean ± SEM, one-way ANOVA). ( E to G ) FACS quantifications of CD45 + (E), MAdCAM-1 + PDGFRβ + (F), and MAdCAM-1 + CD31 + (G) populations, n = 4 mBVO differentiations, pooled mBVOs (mean ± SEM, one-way ANOVA). ( H ) Schematic of antiangiogenic treatments. ( I , K , and L ) Image quantifications of mBVO areas (I), vessel densities (K), and pericyte coverages (L) upon treatments with B20 (10/100 μg/ml) and DC101 (10/100ug/ml), n ≥ 5 mBVOs per condition (mean ± SEM, one-way ANOVA). ( J ) Cryosections of mBVOs (day 30) treated with B20 (100 μg/ml) and DC101 (100 μg/ml) and stained for CD31 and PDGFRβ. Scale bars, 100 μm. A.U., arbitrary units; ns, not significant.

Article Snippet: For antiangiogenic blockade, B6x129 mBVOs were treated every 2 days from day 21 until day 30 with anti-mouse VEGF (10 or 100 μg/ml; B20 biosimilar) ( ) and with InVivoMAb anti-mouse VEGFR2 (DC101) (10 or 100 μg/ml; BioXCell, BE0060).

Techniques: Staining

Journal: Animals : an Open Access Journal from MDPI

Article Title: Microvascularization and Expression of Fibroblast Growth Factor and Vascular Endothelial Growth Factor and Their Receptors in the Mare Oviduct

doi: 10.3390/ani11041099

Figure Lengend Snippet: Primer sequences used for gene transcription analysis by real-time PCR.

Article Snippet: The relative protein abundance of FGFR1, FGFR2 and KDR was measured using specific primary antibodies against FGFR1 (Orb 156864, Biorbyt, Cambridge, UK, dilution 1:500), FGFR2 (SC 6930, Santa Cruz Biotechnology, Dallas, USA, dilution 1:500) and KDR (Orb 99143, Biorbyt, Cambridge, UK, dilution 1:250).

Techniques: Sequencing, Amplification

Journal: Animals : an Open Access Journal from MDPI

Article Title: Microvascularization and Expression of Fibroblast Growth Factor and Vascular Endothelial Growth Factor and Their Receptors in the Mare Oviduct

doi: 10.3390/ani11041099

Figure Lengend Snippet: Relative quantification of FGFR1 , FGFR2 and KDR transcripts in the equine oviduct ( n = 5 samples for each estrous cycle phase; n = 5 for each portion of oviduct analyzed). Comparison of transcripts between the follicular phase, early-luteal phase (Early LP), and mid-luteal (Mid LP) ( A , C , E ). Comparison of transcripts between oviduct portions (infundibulum, ampulla, isthmus), regardless of the phase of the estrous cycle ( B , D , F ). Bars represent mean ± SEM. AU: arbitrary units. Different letters indicate significant differences ( p < 0.05).

Article Snippet: The relative protein abundance of FGFR1, FGFR2 and KDR was measured using specific primary antibodies against FGFR1 (Orb 156864, Biorbyt, Cambridge, UK, dilution 1:500), FGFR2 (SC 6930, Santa Cruz Biotechnology, Dallas, USA, dilution 1:500) and KDR (Orb 99143, Biorbyt, Cambridge, UK, dilution 1:250).

Techniques:

Journal: Animals : an Open Access Journal from MDPI

Article Title: Microvascularization and Expression of Fibroblast Growth Factor and Vascular Endothelial Growth Factor and Their Receptors in the Mare Oviduct

doi: 10.3390/ani11041099

Figure Lengend Snippet: Relative protein abundance of FGFR1, FGFR2 and KDR in the equine oviduct ( n = 5 samples for each estrous cycle phase; n = 5 for each portion of oviduct analyzed). Comparison of relative protein abundance between oviduct portions (infundibulum, ampulla, isthmus), regardless of the phase of the estrous cycle ( A , C , D ), and their respective representative Western blot bands ( B , D , F ). Bars represent mean ± SEM. AU: arbitrary units. Different letters indicate significant differences ( p < 0.05).

Article Snippet: The relative protein abundance of FGFR1, FGFR2 and KDR was measured using specific primary antibodies against FGFR1 (Orb 156864, Biorbyt, Cambridge, UK, dilution 1:500), FGFR2 (SC 6930, Santa Cruz Biotechnology, Dallas, USA, dilution 1:500) and KDR (Orb 99143, Biorbyt, Cambridge, UK, dilution 1:250).

Techniques: Western Blot